Followers | 12 |
Posts | 472 |
Boards Moderated | 0 |
Alias Born | 06/20/2020 |
Friday, February 12, 2021 7:09:40 AM
In my previous post I pointed to Figures 5B and 5C in the peer reviewed publication that showed remdesivir to be a more potent antiviral than brilacidin. At the concentrations tested (1µM and 2.5µM), remdesivir by itself reduced the viral titer by 98% and 99% at 24 hours post infection.
I wouldn’t say that brilacidin adds no value. Instead, I would say I don’t see a reason why Gilead (maker of remdesivir) would want to include brilacidin in their formulation. The graphs make the case that it would be Innovation Pharmaceuticals (maker of brilacidin) who would want to include remdesivir in their formulation.
Other posters have commented on the anti-inflammatory and anti-microbial potential of brilacidin (the 3-in-1 factor). My view is that if brilacidin is inferior as an antiviral there’s no reason to pursue it for these other indications. There are existing anti-inflammatory and anti-microbial drugs that can be used with precision rather than being included scattershot with brilacidin.
My original question remains — Does remdesivir reduce the virus by 98% or 99% in people? Published data shows remdesivir reducing the viral load dramatically in 24 hours. People should get better fast. They don’t. One possibility is that in vitro results do not transfer to the real world.
What does any of this mean for IPIX as a stock? Not much in the short term imo. The share price should rise with future PRs, especially first patient dosed. There is so much money playing the market right now, COVID is still a hot topic, and IPIX has a relatively small market cap all making IPIX a good speculative short term play imo. Don’t get emotionally attached and don’t play with money you can’t afford to lose.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM